Pluristem Therapeutics (NASDAQ:PSTI) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Pluristem Therapeutics (NASDAQ:PSTIGet Rating) in a note issued to investors on Friday. The firm set a “hold” rating on the biotechnology company’s stock.

PSTI stock opened at $1.30 on Friday. The company has a current ratio of 8.22, a quick ratio of 8.22 and a debt-to-equity ratio of 0.57. Pluristem Therapeutics has a 12 month low of $1.06 and a 12 month high of $4.21. The firm has a 50 day moving average of $1.47 and a 200-day moving average of $1.73. The firm has a market capitalization of $42.05 million, a P/E ratio of -0.88 and a beta of 2.00.

Pluristem Therapeutics (NASDAQ:PSTIGet Rating) last released its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($0.31) EPS for the quarter. The firm had revenue of $0.23 million for the quarter. Sell-side analysts predict that Pluristem Therapeutics will post -1.58 EPS for the current year.

A number of hedge funds have recently modified their holdings of the stock. Two Sigma Securities LLC acquired a new stake in shares of Pluristem Therapeutics during the third quarter worth about $29,000. BlackRock Inc. lifted its stake in shares of Pluristem Therapeutics by 100.0% in the 3rd quarter. BlackRock Inc. now owns 13,357 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 6,680 shares during the last quarter. TownSquare Capital LLC purchased a new stake in Pluristem Therapeutics during the 1st quarter worth about $50,000. Values First Advisors Inc. purchased a new position in shares of Pluristem Therapeutics in the 4th quarter valued at about $62,000. Finally, Green Alpha Advisors LLC boosted its position in shares of Pluristem Therapeutics by 16.7% in the 1st quarter. Green Alpha Advisors LLC now owns 78,159 shares of the biotechnology company’s stock valued at $162,000 after purchasing an additional 11,200 shares during the period. 16.94% of the stock is currently owned by institutional investors.

About Pluristem Therapeutics (Get Rating)

Pluristem Therapeutics Inc operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Read More

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.